Cisplatin pharmacokinetics in a patient with renal dysfunction

Archie W. Prestayko, Fredrich C. Luft, Lawrence Einhorn, Stanley T. Crooke

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Plasma and urine platinum concentrations were measured by atomic absorption spectrophotometry during a three‐day course of cisdiamminedichloroplatinum (DDP, cis‐platinum, cisplatin) therapy in a patient with acute renal failure who was being treated with hemodialysis. Twenty‐four hour urine collections, obtained during the oliguric phase, accounted for only 0.36–0.56 percent of the daily DDP dose. The plasma t1/2β of platinum was approximately 240 hours after the last DDP dose. Platinum could be measured in the dialysate only during the first two hours after DDP administration. Although the data show that the t1/2β of DDP is prolonged three fold in a patient with profound renal failure, the clinical implications of these findings await further studies.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalMedical and Pediatric Oncology
Volume5
Issue number1
DOIs
StatePublished - 1978

Fingerprint

Platinum
Cisplatin
Pharmacokinetics
Kidney
Atomic Spectrophotometry
Urine Specimen Collection
Dialysis Solutions
Acute Kidney Injury
Renal Insufficiency
Renal Dialysis
Urine
Therapeutics

Keywords

  • cisplatin
  • pharmacokinetics
  • renal dysfunction

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Cisplatin pharmacokinetics in a patient with renal dysfunction. / Prestayko, Archie W.; Luft, Fredrich C.; Einhorn, Lawrence; Crooke, Stanley T.

In: Medical and Pediatric Oncology, Vol. 5, No. 1, 1978, p. 183-188.

Research output: Contribution to journalArticle

Prestayko, Archie W. ; Luft, Fredrich C. ; Einhorn, Lawrence ; Crooke, Stanley T. / Cisplatin pharmacokinetics in a patient with renal dysfunction. In: Medical and Pediatric Oncology. 1978 ; Vol. 5, No. 1. pp. 183-188.
@article{461d4c1a245f471bbd829f20c1f33416,
title = "Cisplatin pharmacokinetics in a patient with renal dysfunction",
abstract = "Plasma and urine platinum concentrations were measured by atomic absorption spectrophotometry during a three‐day course of cisdiamminedichloroplatinum (DDP, cis‐platinum, cisplatin) therapy in a patient with acute renal failure who was being treated with hemodialysis. Twenty‐four hour urine collections, obtained during the oliguric phase, accounted for only 0.36–0.56 percent of the daily DDP dose. The plasma t1/2β of platinum was approximately 240 hours after the last DDP dose. Platinum could be measured in the dialysate only during the first two hours after DDP administration. Although the data show that the t1/2β of DDP is prolonged three fold in a patient with profound renal failure, the clinical implications of these findings await further studies.",
keywords = "cisplatin, pharmacokinetics, renal dysfunction",
author = "Prestayko, {Archie W.} and Luft, {Fredrich C.} and Lawrence Einhorn and Crooke, {Stanley T.}",
year = "1978",
doi = "10.1002/mpo.2950050125",
language = "English (US)",
volume = "5",
pages = "183--188",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Cisplatin pharmacokinetics in a patient with renal dysfunction

AU - Prestayko, A. W.

AU - Luft, C.

AU - Einhorn, Lawrence

AU - Crooke, S. T.

PY - 1978

Y1 - 1978

N2 - Plasma and urine platinum concentrations were measured by atomic absorption spectrophotometry during a three-day course of cisdiamminedichloroplatinum (DDP, cis-platinum, cisplatin) therapy in a patient with acute renal failure who was being treated with hemodialysis. Twenty-four hour urine collections, obtained during the oliguric phase, accounted for only 0.36-0.56 percent of the daily DDP dose. The plasma t 1/2 β of platinum was approximately 240 hours after the last DDP dose. Platinum could be measured in the dialysate only during the first two hours after DDP administration. Although the data show that the t 1/2 β of DDP is prolonged three fold in a patient with profound renal failure, the clinical implications of these findings await further studies.

AB - Plasma and urine platinum concentrations were measured by atomic absorption spectrophotometry during a three-day course of cisdiamminedichloroplatinum (DDP, cis-platinum, cisplatin) therapy in a patient with acute renal failure who was being treated with hemodialysis. Twenty-four hour urine collections, obtained during the oliguric phase, accounted for only 0.36-0.56 percent of the daily DDP dose. The plasma t 1/2 β of platinum was approximately 240 hours after the last DDP dose. Platinum could be measured in the dialysate only during the first two hours after DDP administration. Although the data show that the t 1/2 β of DDP is prolonged three fold in a patient with profound renal failure, the clinical implications of these findings await further studies.

UR - http://www.scopus.com/inward/record.url?scp=0018196676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018196676&partnerID=8YFLogxK

M3 - Article

C2 - 745586

AN - SCOPUS:0018196676

VL - Vol. 5

SP - 183

EP - 188

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -